ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection.

H. Fernandez, S. Patel, M. Chiles, L. Ratner, R. Crew.

Columbia University Medical Center, NYC.

Meeting: 2016 American Transplant Congress

Abstract number: C17

Keywords: Graft function, HLA antibodies, Kidney transplantation, Rejection

Session Information

Date: Monday, June 13, 2016

Session Name: Poster Session C: Antibody Mediated Rejection: Session #1

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Presence of Highly Immunogenic Mismatch Eplets Is Associated with Development of Chronic Active Antibody-Mediated Rejection: A First Report from Japan.
  • Chronic Active Antibody Mediated Rejection (cABMR): Treatment, Outcomes and Predictors of Graft Loss in a Large Case Series

Intro: CAAMR is an increasingly recognized cause of renal allograft failure with limited treatment options. Many patients with CAAMR have engagement of both T and B cell populations, an interaction that partially involves signaling through the IL-6 pathway. Tocilizumab (Toc), an IL-6 receptor blocker is being investigated in sensitized kidney transplant (KT) recipients.

Methods/Results: Since 2014, 10 KT pts were treated with Toc for CAAMR at CUMC. Patients chosen for Toc treatment had persistent CAAMR despite treatment with IV immunoglobulin (IVIG), rituximab, IV steroids and maximal baseline immunosuppression. The majority of pts were female (n=8), first time kidney recipients (n=5) and had DSA at time of AMR on biopsy (n = 9). Eight pts had prior pRBC and/or pregnancy and 3 were crossmatch positive. One pt had delayed graft function and was on hemodialysis (HD) at the time of Toc initiation. Mean age was 35.3±13.3 yrs and the median time to AMR was 151.1 d. Initial AMR were treated with IVIG (n=9), plasmapharesis (n=3) and/or rituximab (n=7). Patients that failed usual treatment were started on Toc at the discretion of the treating doctor. If 4mg/kg was tolerated, dose was escalated to 8mg/kg monthly. Eight pts received concomitant therapy with IVIg 2 gm/kg every other month. Toc was discontinued in one pt due to persistent HD dependence.

The mean Cr was 1.21±0.27 mg/dL at the time AMR was first diagnosed on biopsy, and increased to 2.14±0.56 mg/dL at Toc initiation. Cr improved to 1.95±0.52 mg/d in 6 pts at 3 mo follow-up and 1.85±0.49 mg/dL at 6 mo follow-up. Mean MFI by Luminex of immunodominant DSA (iDSA) in 8 pts did not change significantly following Toc. During a median of 175 d on Toc, proteinuria at AMR diagnosis was 0.307 and decreased to 0.232 at last follow-up. Of 10 pts, 3 had repeat biopsies during follow up. None showed improvement in the cellular rejection component and one pt had decreased C4d intensity. Interstitial fibrosis and glomerular sclerosis were stable on repeat biopsies. There were 3 complications potentially associated with Toc: 2 pts developed BK viremia; 1 had bacterial diarrhea; 1 pt had pharyngeal swelling found to be benign fibrous tissue, unlikely to be associated with immunosuppression.

Conclusion: Following Toc treatment, Cr appeared to stabilize. iDSA remained unchanged and repeat biopsy did not show significant improvement. Toc treatment will have to be studied further before being widely adopted as treatment for persistent CAAMR.

CITATION INFORMATION: Fernandez H, Patel S, Chiles M, Ratner L, Crew R. Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Fernandez H, Patel S, Chiles M, Ratner L, Crew R. Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/tocilizumab-as-treatment-for-persistent-chronic-active-antibody-mediated-rejection/. Accessed February 24, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.